These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35266417)

  • 41. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
    Confavreux C; Li DK; Freedman MS; Truffinet P; Benzerdjeb H; Wang D; Bar-Or A; Traboulsee AL; Reiman LE; O'Connor PW;
    Mult Scler; 2012 Sep; 18(9):1278-89. PubMed ID: 22307384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
    Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
    Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
    Doggrell SA
    Expert Opin Biol Ther; 2022 Nov; 22(11):1339-1343. PubMed ID: 36317532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.
    Craner M; Al Malik Y; Babtain FA; Alshamrani F; Alkhawajah MM; Alfugham N; Al-Yafeai RH; Aljarallah S; Makkawi S; Qureshi S; Ziehn M; Wahba H
    Neurol Ther; 2022 Dec; 11(4):1457-1473. PubMed ID: 36048334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
    Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW;
    Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
    Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
    Mukhtar H; Yasmeen U; Siddiqa S; Sarfraz Z; Sarfraz A
    Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ofatumumab (Kesimpta) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):203-205. PubMed ID: 33451176
    [No Abstract]   [Full Text] [Related]  

  • 60. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.